They say that vaccines capable of boosting these antibodies could potentially reduce infections more effectively and prevent transmission.Ĭo-senior author of the study, Professor Peter Openshaw, from the National Heart and Lung Institute at Imperial College London, said: “Our results highlight a need for nasal spray vaccines that can boost these local antibodies in the nose and lungs. The researchers call for the next generation of vaccines to include nasal spray or inhaled vaccines that target these antibodies more effectively. It’s now essential to also develop nasal spray vaccines that can provide better protection against infection." Professor Peter Openshaw Imperial's National Heart & Lung Institute "Our current vaccines are designed to reduce severe disease and death and are dramatically effective in this aim. The study also found that whilst current vaccines are effective at boosting blood antibody which can prevent serious illness and death, they do not significantly boost nasal IgA antibodies. It studied almost 450 people who had been hospitalised with COVID-19 between February 2020 and March 2021, before the emergence of Omicron variant and prior to vaccine rollout. The research was led by teams from Imperial College London and the University of Liverpool. The researchers note that studies that directly study these nasal antibodies and reinfections are needed to confirm their results. This might be an important factor behind repeat infections with the SARS-CoV-2 virus and its new variants.” While blood antibodies help to protect against disease, nasal antibodies can prevent infection altogether. Our study found durable immune responses after infection and vaccination, but these key nasal antibodies were shorter-lived than those in the blood. The study also found that vaccination is very effective in creating and boosting antibodies in the blood, which prevent severe disease, but had very little effect on nasal IgA levels.įirst author of the study, Dr Felicity Liew, from the National Heart and Lung Institute at Imperial College London, said: “Before our study, it was unclear how long these important nasal antibodies lasted. These new findings – which are published in eBioMedicine – may explain why people who have recovered from COVID are at risk of reinfection, and especially with Omicron and its subvariants. However, the investigators found that the nasal antibodies were only present in those recently infected and were particularly short-lived against the Omicron variant, compared to earlier variants. "Our study found durable immune responses after infection and vaccination, but these key nasal antibodies were shorter-lived than those in the blood." Dr Felicity Liew Imperial's National Heart & Lung Institute These antibodies are very effective at preventing the virus from entering cells and causing infection. A new study finds that antibodies produced in the nose decline 9 months after infection, while those found in the blood last at least a year.Ī new study finds that antibodies produced in the nose decline nine months after COVID-19 infection, while antibodies found in the blood last at least a year.Īntibodies in the nasal fluid (known as immunoglobulin A, or IgA) provide first-line defence against COVID-19 by blocking SARS-CoV-2 virus when it first enters the respiratory tract.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |